Current and future immune approaches in precision medicine
Update: 2017-07-31
Description
Prof Blay speaks with ecancer at WIN 2017 about open questions and the future of research in immunotherapy.
Among the avenues to explore, Prof Blay outlines the variation in patients response rates and duration, with hyper-progressors posing as much a mystery as best responders.
He lists multiple subtypes across diseases, offering a vast ocean of disease stratification that may never be fully charted, but notes that innovations in trial design and treatment combinations offer chances of achieving the most benefit for even rare diseases.
Prof Blay notes changing availability and cost of genome sequencing and liquid biopsy as opening new futures in bioinformatics, with physics and mathematics coming to the fore in biological understandings of disease and data.
Among the avenues to explore, Prof Blay outlines the variation in patients response rates and duration, with hyper-progressors posing as much a mystery as best responders.
He lists multiple subtypes across diseases, offering a vast ocean of disease stratification that may never be fully charted, but notes that innovations in trial design and treatment combinations offer chances of achieving the most benefit for even rare diseases.
Prof Blay notes changing availability and cost of genome sequencing and liquid biopsy as opening new futures in bioinformatics, with physics and mathematics coming to the fore in biological understandings of disease and data.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
